Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial
Authors:
Top Cited Papers
Open Access
- 15 October 2021
- journal article
- research article
- Published by Springer Nature in Hypertension Research
- Vol. 45 (2) , 221-231
Abstract
Renal denervation is a promising new non-pharmacological treatment for resistant hypertension. However, there is a lack of data from Asian patients. The REQUIRE trial investigated the blood pressure-lowering efficacy of renal denervation in treated patients with resistant hypertension from Japan and South Korea. Adults with resistant hypertension (seated office blood pressure ≥150/90 mmHg and 24-hour ambulatory systolic blood pressure ≥140 mmHg) with suitable renal artery anatomy were randomized to ultrasound renal denervation or a sham procedure. The primary endpoint was change from baseline in 24-hour ambulatory systolic blood pressure at 3 months. A total of 143 patients were included (72 renal denervation, 71 sham control). Reduction from baseline in 24-hour ambulatory systolic blood pressure at 3 months was not significantly different between the renal denervation (−6.6 mmHg) and sham control (−6.5 mmHg) groups (difference: −0.1, 95% confidence interval −5.5, 5.3; p = 0.971). Reductions from baseline in home and office systolic blood pressure (differences: –1.8 mmHg [p = 0.488] and −2.0 mmHg [p = 0.511], respectively), and medication load, did not differ significantly between the two groups. The procedure-/device-related major adverse events was not seen. This study did not show a significant difference in ambulatory blood pressure reductions between renal denervation and a sham procedure in treated patients with resistant hypertension. Although blood pressure reduction after renal denervation was similar to other sham-controlled studies, the sham group in this study showed much greater reduction. This unexpected blood pressure reduction in the sham control group highlights study design issues that will be addressed in a new trial. Clinical trial registration: NCT02918305 (http://www.clinicaltrials.gov).Keywords
This publication has 46 references indexed in Scilit:
- Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical studyHypertension Research, 2012
- Guidelines for the Clinical Use of 24 Hour Ambulatory Blood Pressure Monitoring (ABPM) (JCS 2010)Circulation Journal, 2012
- Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trialThe Lancet, 2010
- Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive AgentsHypertension, 2010
- A Novel Measurement Index for Antihypertensive Medication Burden and Its UseHypertension, 2009
- The Hypertension Paradox — More Uncontrolled Disease despite Improved TherapyNew England Journal of Medicine, 2009
- Cardiovascular Disease and Risk Factors in AsiaCirculation, 2008
- Prevalence and Determinants of Prehypertension in a Japanese General Population: The Jichi Medical School Cohort StudyHypertension Research, 2008
- A Randomized Trial of the Effect of an Angiotensin II Receptor Blocker SR47436 (Irbesartan) on 24-Hour Blood Pressure in Patients with Essential HypertensionHypertension Research, 2008
- Blood pressure and cardiovascular disease in the Asia Pacific regionJournal Of Hypertension, 2003